Pharmacotherapy of gestational trophoblastic neoplasia

Bibliography

• Alazzam M, Tidy J, Hancock BW, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;7:CD007102
   Google Scholar
• Lee C SH, Kim SJ. Gestational trophoblastic disease. 3rd edition. Epidemiology; International Society for the study of trophoblastic diseases; London, UK; 2009
   Google Scholar
• Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105(1):3-4
   PubMedGoogle Scholar
• Rodriguez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease. Expert Opin Pharmacother 2010;11(18):3027-39
   PubMed Web of Science ®Google Scholar
• Ngan HY. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 2004;14(2):202-5
   PubMedGoogle Scholar
• Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956;93(2):361-6
   PubMed Web of Science ®Google Scholar
• Goldstein DP, Winig P, Shirley RL. Actinomycin. D as initial therapy of gestational trophoblastic disease. A reevaluation. Obstet Gynecol 1972;39(3):341-5
   PubMedGoogle Scholar
• Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. Int J Gynaecol Obstet 1998;60(Suppl 1):S77-83
   Google Scholar
• Baptista AM, Belfort P. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2012;119(1):35-8
   PubMedGoogle Scholar
• Hoffman MS, Fiorica JV, Gleeson NC, et al. A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Gynecol Oncol 1996;60(2):292-4
   PubMedGoogle Scholar
• Homesley HD, Blessing JA, Schlaerth J, et al. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol 1990;39(3):305-8
   PubMedGoogle Scholar
• Hammond CB, Borchert LG, Tyrey L, et al. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol 1973;115(4):451-7
   PubMedGoogle Scholar
• Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol 1995;172(2 Pt 1):574-9
   PubMedGoogle Scholar
• Garrett AP, Garner EO, Goldstein DP, et al. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002;47(5):355-62
   PubMedGoogle Scholar
• Berkowitz RS, Goldstein DP, Bernstein MR. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986;23(1):111-18
   PubMedGoogle Scholar
• Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol 1985;152(1):59-62
   PubMedGoogle Scholar
• Khan F, Everard J, Ahmed S, et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003;89(12):2197-201
   PubMedGoogle Scholar
• Elit L, Covens A, Osborne A. High-dose methotrexate for gestational trophoblastic disease. Gynecol Oncol 1994;54:282-7
   PubMedGoogle Scholar
• Bagshawe KD, Dent J, Newlands ES, et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989;96(7):795-802
   PubMedGoogle Scholar
• McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20(7):1838-44
   PubMed Web of Science ®Google Scholar
• Soper JT, Clarke-Pearson DL, Berchuck A, et al. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54(1):76-9
   PubMed Web of Science ®Google Scholar
• Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996;174(6):1917-23; discussion 1923-1914
   PubMedGoogle Scholar
• Twiggs LB. Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecol Oncol 1983;16(2):190-5
   PubMedGoogle Scholar
• Schlaerth JB, Morrow CP, Nalick RH, et al. Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984;19(1):53-6
   PubMedGoogle Scholar
• Petrilli ES, Twiggs LB, Blessing JA, et al. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987;60(9):2173-6
   PubMedGoogle Scholar
• Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011;29(7):825-31
   PubMedGoogle Scholar
• Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975;36(3):863-6
   PubMedGoogle Scholar
• Kohorn EI. Single-agent chemotherapy for nonmetastatic gestational trophoblastic neoplasia. Perspectives for the 21st century after three decades of use. J Reprod Med 1991;36(1):49-55
   PubMedGoogle Scholar
• Berkowitz RS, Goldstein DP, Bernstein MR. Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecol Oncol 1990;36(1):56-9
   PubMedGoogle Scholar
• Shah NT, Barroilhet L, Berkowitz RS, et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med 2012;57(5-6):211-18
   PubMedGoogle Scholar
• Growdon WB, Wolfberg AJ, Goldstein DP, et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009;112(2):353-7
   PubMedGoogle Scholar
• Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009;112(3):654-62
   PubMed Web of Science ®Google Scholar
• Taylor F, Grew T, Everard J, et al. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer 2013;49(15):3184-90
   PubMedGoogle Scholar
• Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012;107(11):1810-14
   PubMed Web of Science ®Google Scholar
• Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol 2012;125(3):572-5
   PubMedGoogle Scholar
• Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;12:CD008891
   PubMed Web of Science ®Google Scholar
• Sharma S, Jagdev S, Coleman RE, et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer 1999;81(6):1037-41
   PubMedGoogle Scholar
• Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust NZ J Obstet Gynaecol 2005;45(2):161-4
   PubMedGoogle Scholar
• Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2008;103(1):33-7
   PubMedGoogle Scholar
• Mousavi A, Cheraghi F, Yarandi F, et al. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease. Int J Gynaecol Obstet 2012;116(1):39-42
   PubMedGoogle Scholar
• Lertkhachonsuk AA, Israngura N, Wilailak S, et al. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer 2009;19(5):985-8
   PubMedGoogle Scholar
• Aghajanian C. Treatment of low-risk gestational trophoblastic neoplasia. J Clin Oncol 2011;29(7):786-8
   PubMed Web of Science ®Google Scholar
• Covens A, Filiaci VL, Burger RA, et al. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Cancer 2006;107(6):1280-6
   PubMedGoogle Scholar
• Goldstein DP, Berkowitz RS, Bernstein MR. Reproductive performance after molar pregnancy and gestational trophoblastic tumors. Clin Obstet Gynecol 1984;27(1):221-7
   PubMedGoogle Scholar
• Dobson LS, Lorigan PC, Coleman RE, et al. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer 2000;82(9):1547-52
   PubMedGoogle Scholar
• Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am 2012;26(1):111-31
   PubMed Web of Science ®Google Scholar
• Winter MC EJ, Kahn FA, Tidy JA, et al. Second line chemotherapy for low risk GTN: 10 years of results from the Sheffield Centre for Trophoblastic disease, UK. World GTD Congress, Budapest; 2011
   Google Scholar
• Lurain JR, Chapman-Davis E, Hoekstra AV, et al. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. J Reprod Med 2012;57(7-8):283-7
   PubMedGoogle Scholar
• McGrath S, Short D, Harvey R, et al. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 2010;102(5):810-14
   PubMed Web of Science ®Google Scholar
• Bagshawe KD. Treatment of high-risk choriocarcinoma. J Reprod Med 1984;29(11):813-20
   PubMedGoogle Scholar
• Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989;73(3 Pt 1):357-62
   PubMed Web of Science ®Google Scholar
• Feng F, Xiang Y, Wan X, et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Ann Oncol 2011;22(7):1588-94
   PubMedGoogle Scholar
• Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006;51(10):767-72
   PubMed Web of Science ®Google Scholar
• Seckl MJ, Rustin GJ. Late toxicity after therapy of gestational trophoblastic neoplasia. International Society for the Study of Trophoblastic Diseases. 2009. Available from: http://www.isstd.org/isstd/chapter21.html [Accessed 26 September 2103]
   Google Scholar
• Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988;31(3):439-44
   PubMed Web of Science ®Google Scholar
• Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992;80(5):817-20
   PubMedGoogle Scholar
• Soper JT, Evans AC, Clarke-Pearson DL, et al. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994;83(1):113-17
   PubMedGoogle Scholar
• Newlands ES, Bower M, Holden L, et al. The management of high-risk gestational trophoblastic tumours (GTT). Int J Gynaecol Obstet 1998;60(Suppl 1):S65-70
   PubMedGoogle Scholar
• Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT–25 years experiences of KRI-TRD. Int J Gynaecol Obstet 1998;60(Suppl 1):S85-96
   Google Scholar
• Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 2003;91(3):552-7
   PubMed Web of Science ®Google Scholar
• Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 2006;16(3):1432-8
   PubMed Web of Science ®Google Scholar
• Lu WG, Ye F, Shen YM, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer 2008;18(2):357-62
   PubMed Web of Science ®Google Scholar
• Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. J Reprod Med 2010;55(5-6):199-207
   PubMed Web of Science ®Google Scholar
• Chauhan A, Dave K, Desai A, et al. High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience. J Reprod Med 2010;55(7-8):333-40
   PubMedGoogle Scholar
• Cyriac S, Rajendranath R, Sridevi V, et al. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2011;115(1):37-9
   PubMedGoogle Scholar
• Bianconi MI, Otero S, Moscheni O, et al. Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital. J Reprod Med 2012;57(7-8):341-9
   PubMedGoogle Scholar
• Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med 2012;57(5-6):231-6
   PubMed Web of Science ®Google Scholar
• Fulop V, Szigetvari I, Szepesi J, et al. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years. J Reprod Med 2012;57(7-8):310-18
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013;31(2):280-6
   PubMed Web of Science ®Google Scholar
• Gordon AN, Gershenson DM, Copeland LJ, et al. High-risk metastatic gestational trophoblastic disease. Obstet Gynecol 1985;65(4):550-6
   PubMedGoogle Scholar
• Lurain JR, Brewer JI. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy. Obstet Gynecol 1985;65(6):830-6
   PubMedGoogle Scholar
• Agarwal R AC, Everard J, et al. Management and survival of patients wth FIGO high-risk gestational trophoblastic neoplasia from 1995 to 2010: the UK experience. J Reprod Med 2013; in Press
   Google Scholar
• Wan XR, Xiang Y, Yang XY, et al. Efficacy of FAEV regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor. Zhonghua Fu Chan Ke Za Zhi 2006;41(2):88-90
   PubMedGoogle Scholar
• Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. J Reprod Med 2009;54(2):88-94
   PubMedGoogle Scholar
• Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). Int J Gynecol Cancer 2004;14(2):360-5
   PubMedGoogle Scholar
• Wang S, An R, Han X, et al. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecol Oncol 2006;103(3):1105-8
   PubMedGoogle Scholar
• El-Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncol 2007;8(8):715-24
   PubMedGoogle Scholar
• Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997;15(7):2636-43
   PubMed Web of Science ®Google Scholar
• Newlands ES, Bagshawe KD, Begent RH, et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991;98(6):550-7
   PubMedGoogle Scholar
• Deng L, Zhang J, Wu T, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013;1:CD005196
   PubMedGoogle Scholar
• Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 2012;9(7):2444-53
   PubMedGoogle Scholar
• Houck W, Abonour R, Vance G, et al. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 2004;22(11):2155-8
   PubMedGoogle Scholar
• El-Helw LM, Seckl MJ, Haynes R, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer 2005;93(6):620-1
   PubMedGoogle Scholar
• Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376(9742):717-29
   PubMed Web of Science ®Google Scholar
• Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2012;57(5-6):219-24
   PubMed Web of Science ®Google Scholar
• Mao Y, Wan X, Lv W, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Int J Gynaecol Obstet 2007;98(1):44-7
   PubMed Web of Science ®Google Scholar
• Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000;18(4):854-9
   PubMed Web of Science ®Google Scholar
• Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med 2004;49(6):443-6
   PubMedGoogle Scholar
• Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005;97(2):618-23
   PubMed Web of Science ®Google Scholar
• El-Lamie IK, El Sayed HM, Badawie AG, et al. Evolution of treatment of high-risk metastatic gestational trophoblastic tumors: ain Shams University experience. Int J Gynecol Cancer 2006;16(2):866-74
   PubMedGoogle Scholar
• Azab M, Droz JP, Theodore C, et al. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989;64(9):1829-32
   PubMedGoogle Scholar
• DuBeshter B, Berkowitz RS, Goldstein DP, et al. Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease. J Reprod Med 1989;34(3):189-92
   PubMedGoogle Scholar
• Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol 2008;19(9):1578-83
   PubMed Web of Science ®Google Scholar
• Theodore C, Azab M, Droz JP, et al. Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer 1989;64(9):1824-8
   PubMedGoogle Scholar
• Soper JT, Evans AC, Rodriguez G, et al. Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol 1995;56(3):421-4
   PubMedGoogle Scholar
• Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med 2004;49(6):438-42
   PubMedGoogle Scholar
• Manopunya M, Suprasert P. Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. Asian Pac J Cancer Prev 2012;13(1):387-90
   PubMedGoogle Scholar
• Wan X, Xiang Y, Yang X, et al. Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor. J Reprod Med 2007;52(10):941-4
   PubMedGoogle Scholar
• Lotz JP, Andre T, Donsimoni R, et al. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995;75(3):874-85
   PubMedGoogle Scholar
• Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010;55(5-6):194-8
   PubMedGoogle Scholar
• Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006;51(10):773-6
   PubMed Web of Science ®Google Scholar
• Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980;46(12):2723-30
   PubMedGoogle Scholar
• Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008;53(7):493-8
   PubMed Web of Science ®Google Scholar
• Neubauer NL, Latif N, Kalakota K, et al. Brain metastasis in gestational trophoblastic neoplasia: an update. J Reprod Med 2012;57(7-8):288-92
   PubMed Web of Science ®Google Scholar
• Small W Jr, Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology 1996;200(1):277-80
   PubMed Web of Science ®Google Scholar
• Yordan EL Jr, Schlaerth J, Gaddis O, et al. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987;69(4):627-30
   PubMedGoogle Scholar
• Cagayan MS, Lu-Lasala LR. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: a 12-year review at the Philippine General Hospital. J Reprod Med 2006;51(10):785-92
   PubMedGoogle Scholar
• Evans AC Jr, Soper JT, Clarke-Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995;59(2):226-30
   PubMedGoogle Scholar
• Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002;47(6):465-71
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7(7):900-3
   PubMed Web of Science ®Google Scholar
• Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med 2012;57(5-6):262-9
   PubMedGoogle Scholar
• Crawford RA, Newlands E, Rustin GJ, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 1997;104(1):105-9
   PubMedGoogle Scholar
• Bakri YN, Subhi J, Amer M, et al. Liver metastases of gestational trophoblastic tumor. Gynecol Oncol 1993;48(1):110-13
   PubMedGoogle Scholar
• Lang EK. Reduced systemic toxicity from superselective chemoembolization compared with systemic chemotherapy in patients with high-risk metastatic gestational trophoblastic disease. Cardiovasc Intervent Radiol 1997;20(4):280-4
   PubMedGoogle Scholar
• Kurman RJ. The morphology, biology, and pathology of intermediate trophoblast: a look back to the present. Hum Pathol 1991;22(9):847-55
   PubMedGoogle Scholar
• Kingdon SJ, Coleman RE, Ellis L, et al. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med 2012;57(7-8):293-6
   PubMedGoogle Scholar
• Bonazzi C, Urso M, Dell'Anna T, et al. Placental site trophoblastic tumor: an overview. J Reprod Med 2004;49(8):585-8
   PubMedGoogle Scholar
• Chang YL, Chang TC, Hsueh S, et al. Prognostic factors and treatment for placental site trophoblastic tumor-report of 3 cases and analysis of 88 cases. Gynecol Oncol 1999;73(2):216-22
   PubMed Web of Science ®Google Scholar
• Gillespie AM, Liyim D, Goepel JR, et al. Placental site trophoblastic tumour: a rare but potentially curable cancer. Br J Cancer 2000;82(6):1186-90
   PubMedGoogle Scholar
• Feltmate CM, Genest DR, Wise L, et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001;82(3):415-19
   PubMedGoogle Scholar
• Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002;47(6):460-4
   PubMedGoogle Scholar
• Hoekstra AV, Keh P, Lurain JR. Placental site trophoblastic tumor: a review of 7 cases and their implications for prognosis and treatment. J Reprod Med 2004;49(6):447-52
   PubMedGoogle Scholar
• Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 2005;99(3):603-7
   PubMedGoogle Scholar
• Zhao J, Xiang Y, Wan XR, et al. Clinical and pathologic characteristics and prognosis of placental site trophoblastic tumor. J Reprod Med 2006;51(12):939-44
   PubMedGoogle Scholar
• Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009;374(9683):48-55
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang X, Xie X. Clinical features of 17 cases of placental site trophoblastic tumor. Int J Gynaecol Obstet 2011;115(2):204-5
   PubMedGoogle Scholar
• Hyman DM, Bakios L, Gualtiere G, et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol 2013;129(1):58-62
   PubMedGoogle Scholar
• van Trommel NE, Lok CA, Bulten H, et al. Long-term outcome of placental site trophoblastic tumor in The Netherlands. J Reprod Med 2013;58(5-6):224-8
   PubMedGoogle Scholar
• Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008;53(7):519-24
   PubMedGoogle Scholar
• Pisal N, North C, Tidy J, et al. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 2002;87(2):190-2
   PubMed Web of Science ®Google Scholar
• Fu J, Fang F, Xie L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;10:CD007289
   PubMed Web of Science ®Google Scholar